S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE

• A. Lal,
• C. Brown,
• T. Coates,
• T. Kalfa,
• J.L. Kwiatkowski,
• J. Brevard,
• C. Trenor,
• K. Wood,
• S. Sheth

Affiliations

A. Lal

1 University of California San Francisco, San Francisco, UNITED STATES

C. Brown

2 Children’s Healthcare of Atlanta, Atlanta, UNITED STATES

T. Coates

3 University of Southern California Keck School of Medicine, Los Angeles, UNITED STATES

T. Kalfa

4 Cincinnati Children’s Hospital Medical Center, Cincinnati, UNITED STATES

J.L. Kwiatkowski

5 Children’s Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, UNITED STATES

J. Brevard

6 Forma Therapeutics, Inc, Watertown, UNITED STATES

C. Trenor

6 Forma Therapeutics, Inc, Watertown, UNITED STATES

K. Wood

6 Forma Therapeutics, Inc, Watertown, UNITED STATES

S. Sheth

7 Weill Cornell Medicine, New York City, UNITED STATES